-- Telix Pharmaceuticals (ASX:TLX) successfully priced and upsized its 1.50% convertible notes due 2031 to $600 million from $550 million, issued through its wholly owned subsidiary, Telix Pharmaceuticals Investments, reflecting strong investor demand, according to a Wednesday Australian bourse filing.
The notes can be converted into the company's ordinary shares at an initial conversion price of $13.85, which reflects a premium of around 38% over the reference share price, per the filing.
The bonds pay interest quarterly and mature around April 2031, unless they are redeemed or converted earlier, the filing said.
The company will simultaneously repurchase and cancel over 85% of its 2029 convertible bonds through a reverse bookbuild process, with settlement for both transactions expected on April 22, the filing added.